Compare · AEE vs VIVO
AEE vs VIVO
Side-by-side comparison of Ameren Corporation (AEE) and VivoPower PLC (VIVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEE and VIVO operate in Power Generation (Utilities), so they compete in similar markets.
- AEE is the larger of the two at $29.58B, about 221.7x VIVO ($133.4M).
- Over the past year, AEE is up 5.9% and VIVO is down 32.9% - AEE leads by 38.8 points.
- AEE has been more active in the news (10 items in the past 4 weeks vs 4 for VIVO).
- AEE has more recent analyst coverage (25 ratings vs 3 for VIVO).
Ameren Corporation
Ameren Corporation, together with its subsidiaries, operates as a public utility holding company in the United States. It operates through four segments: Ameren Missouri, Ameren Illinois Electric Distribution, Ameren Illinois Natural Gas, and Ameren Transmission. The company engages in the rate-regulated electric generation, transmission, and distribution activities; and rate-regulated natural gas distribution and transmission businesses. It primarily generates electricity through coal, nuclear, and natural gas, as well as renewable sources, such as hydroelectric, wind, methane gas, and solar. The company serves residential, commercial, and industrial customers. The company was founded in 1881 and is headquartered in St. Louis, Missouri.
VivoPower PLC
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Latest AEE
- Ameren Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SVP Finance Martin Ryan J sold $106,689 worth of shares (971 units at $109.88), decreasing direct ownership by 3% to 25,595 units (SEC Form 4)
- Ameren Illinois Announces Pricing of First Mortgage Bonds due 2036
- SVP and CATO Shaw Theresa A sold $35,402 worth of shares (325 units at $108.93), decreasing direct ownership by 0.99% to 32,340 units (SEC Form 4)
- Ameren Corporation Directors Declare Quarterly Dividend
- Group President, Utilities Moehn Michael L sold $708,240 worth of shares (6,500 units at $108.96), decreasing direct ownership by 3% to 199,689 units (SEC Form 4)
- Ameren Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Ameren Corporation
- SEC Form S-3ASR filed by Ameren Corporation
- SEC Form 10-Q filed by Ameren Corporation
Latest VIVO
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Approves Independent Listing of 2.2GW Non-Nordic AI Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Fully Retires US$28.8 Million Shareholder Debt Principal, Strengthening Balance Sheet Ahead of Nordic AI Infrastructure Buildout
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Secures US$50 Million PIPE At US$7.50 Conversion Price Per Share
- SEC Form 6-K filed by VivoPower PLC
- VivoPower Appoints Group Finance Director
- SEC Form 6-K filed by VivoPower PLC
- Noble Capital Markets Initiates Equity Research Coverage on VivoPower